Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses. It is hypothesized that AK002 is more effective than placebo control (alternative hypothesis) in reducing the number of eosinophils per high power field (HPF) in gastric and/or duodenal biopsies before and after receiving AK002 or placebo versus no difference between AK002 and placebo control (null hypothesis).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03496571
Study type Interventional
Source Allakos, Inc.
Contact Henrik Rasmussen, MD, PhD
Phone 443-699-5230
Email hrasmussen@allakos.com
Status Recruiting
Phase Phase 2
Start date July 18, 2018
Completion date September 2019

See also
  Status Clinical Trial Phase
Completed NCT00148603 - Montelukast in the Treatment of Duodenal Eosinophilia N/A
Not yet recruiting NCT03678545 - DEGS - Dupilumab for Eosinophilic Gastritis Study Phase 2
Enrolling by invitation NCT03664960 - An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Phase 2
Completed NCT00267475 - Data Bank for Eosinophilic Disorders N/A
Terminated NCT01814059 - Sirolimus for Eosinophil-Associated Gastrointestinal Disorders Phase 1
Completed NCT00266565 - Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Phase 1/Phase 2
Terminated NCT01212016 - Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders N/A
Recruiting NCT03320369 - CEGIR 7809: Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis N/A
Active, not recruiting NCT02897271 - Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort N/A